HIMS slides over 4% as technicals worsen following FTC complaint and lawsuit

Traders Union
All News
Stocks
Hims & Hers Health slides 4.02% today

Highlights

Hims & Hers Health faces a securities class action lawsuit concerning FTC allegations of mishandling health data, billing, and cancellations.
The company expanded with new testosterone therapies in men's health and extended prescription weight management services to Germany.
Shares of Hims & Hers Health are under pressure with a forecasted range of $26.74 to $29.53 over the next 5 days, with momentum indicators signaling weak downside bias and potential for continued sideways trading.

Lawsuit disclosure and FTC case weigh against new product momentum

Hims & Hers Health disclosed a securities class action lawsuit related to an earlier Federal Trade Commission federal complaint from July 29, 2026. The complaint alleges improper handling of consumer health information, premature billing, and issues with subscription cancellation practices. In response, the company has filed a motion to dismiss the FTC's claims, stating that users consented to data sharing through its privacy policy. The period also saw product expansion into men's health with new testosterone therapies and an extension of prescription weight management services to Germany, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, highlights that Hims & Hers Health is facing multiple headwinds. He notes that the securities lawsuit, combined with FTC allegations, has severely dampened sentiment and undermined confidence. The stock's persistent failure to reclaim its 20- and 50-day moving averages signals entrenched selling pressure. Weak technical momentum, as seen in the ADX and MACD, compounds these risks. "With ongoing litigation and lack of decisive support from buyers, I see little reason for optimism in the near term," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, sees opportunity for Hims & Hers Health despite recent setbacks. He emphasizes the company's rapid expansion into international markets and new health products, which supports long-term growth. The sustained position above the 200-day moving average reflects an intact bullish structure. Improved sentiment could quickly trigger a move through resistance and reestablish upward momentum. "With innovation and supportive long-term trends, I expect further growth potential for HIMS if volatility subsides," Karapetjanc states.

Jainam Mehta, market strategist, views the conflicting momentum signals as a tactical opportunity. He notes the divergence between weak downside follow-through and hints of intraday buyer support. The volatility band between $26.74 and $29.53 sets the stage for short-term range trading or a potential breakout. "Traders watching for an oversold bounce or a breakdown below support could find attractive risk-reward setups here," Mehta says.

Short-term seller strength as technical support holds amid weak momentum

Hims & Hers Health trades below its 20-day and 50-day moving averages ($29.19 and $29.16), but remains above its 200-day moving average at $27.17, pointing to short- and medium-term pressure from sellers but a positive long-term trend structure. The near-term ceiling stands at $28.21 and the near-term floor is at $27.54, identifying current support and resistance zones, with Ichimoku Kijun resistance at $29.06 further confirming intermediate pressure. The MACD forecast is negative and the Average Directional Index (ADX) sits at 12, signaling weak momentum and a lack of clear direction. The Relative Strength Index (RSI) shows a buy forecast near neutral levels, while the CCI and Stochastic RSI are both in neutral or mild sell territory. Bull/Bear Power (BBP) is slightly positive, indicating buyers have a mild edge intraday, alongside an “Oversold” reading hinting at potential for a reversal. The stock is at $27.95, down $1.17 or 4.02% today, after opening with a downside gap of roughly 1.58%. The price is near the daily low; intraday volatility stands at 3.47%. The tone is pressured after the open with momentum signals showing a divergence between weak downside momentum and mild signs of buyer interest.

Earlier, analysts noted that Hims & Hers Health was facing heightened legal and regulatory risks, leading to a baseline expectation for price consolidation within a volatility band. The current analysis adds support to this view as selling pressure persists, with the immediate risk centered on whether HIMS can maintain support above $26.74 in the coming sessions.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.